The U.S. FDA has approved Roche's Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a …
Injectable Medication
Novo Nordisk to Begin Phase 3 Development of Semaglutide for Type 2 Diabetes
Semaglutide successfully completed phase 2 development in 2010. At that time, it was decided to compare semaglutide with…
New Observational Data Shows Patients Prefer Victoza
New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of H…
Sanofi Presents New Data on Lixisenatide, an Investigational GLP-1 Agonist, for Type 2 Diabetes
Sanofi has presented data from two studies demonstrating Lyxumia (lixisenatide), a once-daily investigational GLP-1 agon…
The Significance of the Victoza Product Label Update
Novo Nordisk’s widely popular GLP-1 analog Victoza made headlines at the beginning of the year when celebrity chef…
EU Approves Type 2 Diabetes Drug Byetta for Use with Basal Insulin
The European Commission has granted marketing authorization to Byetta (exenatide twice-daily) as an adjunctive therapy t…
An Interview with Paula Deen: Adjusting to Life with Type 2 Diabetes
"Paula Deen is not the diabetes poster child," said Ambre Morely, associate director of product communications at Novo N…
Type 2 Diabetes Drug Byetta Recommended as Add-on Therapy to Insulin
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinio…
Amylin’s New Type 2 Diabetes Treatment, Bydureon, Now Available in US Pharmacies
The newly approved type 2 diabetes drug Bydureon, made by Amylin Pharmaceuticals and Alkermes plc, is now available by …
FDA Approves Type 2 Diabetes Drug Bydureon
Amylin Pharmaceuticals, Inc. and Alkermes plc received FDA approval for Bydureon, a next generation once-weekly treatmen…